Benjamin P Linas1, Devra M Barter, Jared A Leff, Madeline DiLorenzo, Bruce R Schackman, Charles R Horsburgh, Sabrina A Assoumou, Joshua A Salomon, Milton C Weinstein, Arthur Y Kim, Kenneth A Freedberg. 1. aSection of Infectious Diseases, Department of Medicine, Boston Medical Center bDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts cDepartment of Public Health, Weill Cornell Medical College, New York, New York dDivision of General Medicine, Massachusetts General Hospital eDivision of Infectious Diseases, Massachusetts General Hospital fDepartment of Global Health and Population gDepartment of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: To evaluate the effectiveness and cost-effectiveness of strategies to treat hepatitis C virus (HCV) in HIV/HCV coinfected patients in the United States. PARTICIPANTS: Simulated cohort of HIV/HCV genotype 1 coinfected, noncirrhotic, HCV treatment-naive individuals enrolled in US HIV guideline-concordant care. DESIGN/ INTERVENTIONS: Monte Carlo simulation comparing five strategies: no treatment; dual therapy with pegylated-interferon (PEG) and ribavirin (RBV); 'PEG/RBV trial' in which all patients initiate dual therapy and switch to triple therapy upon failure; 'IL28B triage' in which patients initiate either dual therapy or triple therapy based on their IL28B allele type; and PEG/RBV and telaprevir (TPV) triple therapy. Sensitivity analyses varied efficacies and costs and included a scenario with interferon (IFN)-free therapy. MAIN MEASURES: Sustained virologic response (SVR), life expectancy, discounted quality-adjusted life expectancy (QALE), lifetime medical costs, and incremental cost-effectiveness ratios (ICERs) in $/quality-adjusted life years (QALY) gained. RESULTS: 'PEG/RBV trial,' 'IL28B triage,' and 'triple therapy' each provided 72% SVR and extended QALE compared with 'dual therapy' by 1.12, 1.14, and 1.15 QALY, respectively. The ICER of 'PEG/RBV trial' compared with 'dual therapy' was $37 500/QALY. 'IL28B triage' and 'triple therapy' provided little benefit compared with 'PEG/RBV trial,' and both had ICERs exceeding $300 000/QALY. In sensitivity analyses, IFN-free treatment attaining 90% SVR had an ICER less than $100 000/QALY compared with 'PEG/RBV trial' when its cost was $109 000 or less (125% of the cost of PEG/RBV/TVR). CONCLUSION: HCV protease inhibitors are most efficiently used in HIV/HCV coinfection after a trial of PEG/RBV, sparing protease inhibitors for those who attain rapid virologic response and SVR. The cost-effectiveness of IFN-free regimens for HIV/HCV coinfection will depend on the cost of these therapies.
OBJECTIVES: To evaluate the effectiveness and cost-effectiveness of strategies to treat hepatitis C virus (HCV) in HIV/HCV coinfected patients in the United States. PARTICIPANTS: Simulated cohort of HIV/HCV genotype 1 coinfected, noncirrhotic, HCV treatment-naive individuals enrolled in US HIV guideline-concordant care. DESIGN/ INTERVENTIONS: Monte Carlo simulation comparing five strategies: no treatment; dual therapy with pegylated-interferon (PEG) and ribavirin (RBV); 'PEG/RBV trial' in which all patients initiate dual therapy and switch to triple therapy upon failure; 'IL28B triage' in which patients initiate either dual therapy or triple therapy based on their IL28B allele type; and PEG/RBV and telaprevir (TPV) triple therapy. Sensitivity analyses varied efficacies and costs and included a scenario with interferon (IFN)-free therapy. MAIN MEASURES: Sustained virologic response (SVR), life expectancy, discounted quality-adjusted life expectancy (QALE), lifetime medical costs, and incremental cost-effectiveness ratios (ICERs) in $/quality-adjusted life years (QALY) gained. RESULTS: 'PEG/RBV trial,' 'IL28B triage,' and 'triple therapy' each provided 72% SVR and extended QALE compared with 'dual therapy' by 1.12, 1.14, and 1.15 QALY, respectively. The ICER of 'PEG/RBV trial' compared with 'dual therapy' was $37 500/QALY. 'IL28B triage' and 'triple therapy' provided little benefit compared with 'PEG/RBV trial,' and both had ICERs exceeding $300 000/QALY. In sensitivity analyses, IFN-free treatment attaining 90% SVR had an ICER less than $100 000/QALY compared with 'PEG/RBV trial' when its cost was $109 000 or less (125% of the cost of PEG/RBV/TVR). CONCLUSION: HCV protease inhibitors are most efficiently used in HIV/HCV coinfection after a trial of PEG/RBV, sparing protease inhibitors for those who attain rapid virologic response and SVR. The cost-effectiveness of IFN-free regimens for HIV/HCV coinfection will depend on the cost of these therapies.
Authors: Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Juan A Pineda; Antonio Caruz; Federico A Di Lello; Angela Camacho; Pilar Mesa; Karin Neukam; Antonio Rivero-juárez; Juan Macías; Jesús Gómez-Mateos; Antonio Rivero Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Annelies S Zinkernagel; Viktor von Wyl; Bruno Ledergerber; Martin Rickenbach; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Philip E Tarr; Milos Opravil; Enos Bernasconi; Patrick Schmid; Rainer Weber Journal: Antivir Ther Date: 2006
Authors: Bruce R Schackman; Kelly A Gebo; Rochelle P Walensky; Elena Losina; Tammy Muccio; Paul E Sax; Milton C Weinstein; George R Seage; Richard D Moore; Kenneth A Freedberg Journal: Med Care Date: 2006-11 Impact factor: 2.983
Authors: Anne S Spaulding; Arthur Y Kim; Amy Jo Harzke; Jean C Sullivan; Benjamin P Linas; Arthur Brewer; Jeff Dickert; Barbara H McGovern; Lara B Strick; Robert Trestman; Warren J Ferguson Journal: Top Antivir Med Date: 2013 Feb-Mar
Authors: M Vera-Llonch; M Martin; J Aggarwal; M Donepudi; M Bayliss; T Goss; Z Younossi Journal: Aliment Pharmacol Ther Date: 2013-06-03 Impact factor: 8.171
Authors: Christopher A K Y Chong; Anar Gulamhussein; E Jenny Heathcote; Les Lilly; Morris Sherman; Gary Naglie; Murray Krahn Journal: Am J Gastroenterol Date: 2003-03 Impact factor: 10.864
Authors: Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina Journal: Med Care Date: 2015-04 Impact factor: 2.983
Authors: Ali Jalali; Danielle A Ryan; Kathryn E McCollister; Lisa A Marsch; Bruce R Schackman; Sean M Murphy Journal: J Subst Abuse Treat Date: 2020-03
Authors: Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim Journal: Ann Intern Med Date: 2015-05-05 Impact factor: 51.598
Authors: Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas Journal: Addiction Date: 2015-01 Impact factor: 7.256
Authors: Brittany A Shelton; Deirdre Sawinski; Benjamin P Linas; Peter P Reese; Margaux Mustian; Mitch Hungerpiller; Rhiannon D Reed; Paul A MacLennan; Jayme E Locke Journal: Am J Transplant Date: 2018-08-30 Impact factor: 9.369
Authors: Rodolfo Castro; Louise Crathorne; Hugo Perazzo; Julio Silva; Chris Cooper; Jo Varley-Campbell; Daniel Savignon Marinho; Marcela Haasova; Valdilea G Veloso; Rob Anderson; Chris Hyde Journal: BMC Med Res Methodol Date: 2018-06-13 Impact factor: 4.615